Pharmacogenomic topic · dashboard states: NM · PM · IM · UM
PGx describes inherited differences in drug handling. AUC measures total exposure, not benefit or toxicity by itself. Ask whether the pathway clears a drug or activates it: slower clearance can raise exposure; slower activation can reduce benefit. Lower inactive-metabolite exposure does not imply lost efficacy.
Dashboard vocabulary: NM = Normal metabolizer; PM = Poor metabolizer; IM = Intermediate metabolizer; UM = Ultrarapid metabolizer. RM = Rapid metabolizer appears only under CYP2C19; EXP = Expresser appears only under CYP3A5. These interface labels do not establish clinical phenotypes for every gene. Prescribing uses the laboratory report, current guidance and monitoring.
Test at a glance
Encodes OATP1B1, which transports medicines from blood into the liver.
Clinical role
Reduced transport can increase statin exposure and muscle-toxicity risk, especially with simvastatin. CPIC guides statin choice and dose.
Practical pearls
Clinical terms are decreased or poor transporter function, not slow metabolism.
Simvastatin acid can rise even when the parent-drug row is unchanged.
Safety / monitoring
Review muscle symptoms, interactions and dose. Preserve needed cholesterol treatment with an appropriate statin or regimen.
Self-check
Is SLCO1B1 a drug-metabolizing enzyme? No. It encodes a transporter.
Does poor function rule out every statin? No. Choice and dose are drug-specific.